These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36203360)

  • 1. Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer.
    Bote H; Mesas A; Baena J; Herrera M; Paz-Ares L
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):289-300. PubMed ID: 36203360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.
    Wu L; Zhang Z; Bai M; Yan Y; Yu J; Xu Y
    Cell Commun Signal; 2023 May; 21(1):119. PubMed ID: 37221584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors.
    Nardin S; Sacco G; Lagodin D'Amato A; Barcellini L; Rovere M; Santamaria S; Marconi S; Coco S; Genova C
    Expert Opin Pharmacother; 2024 Jun; 25(8):1051-1069. PubMed ID: 38935538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.
    Cella E; Zullo L; Marconi S; Rossi G; Coco S; Dellepiane C; Alama A; Rozeboom L; Bennicelli E; Parisi F; Sacco G; Barletta G; Zinoli L; Tagliamento M; Pronzato P; Genova C
    Expert Opin Biol Ther; 2022 Oct; 22(10):1259-1273. PubMed ID: 35994596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Non-small Cell Lung Cancer: a Review.
    Sequeira T; Almodovar MT
    Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):55-65. PubMed ID: 38499025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy.
    Leal T; Socinski MA
    Expert Rev Anticancer Ther; 2023; 23(8):817-833. PubMed ID: 37486248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Yang G; Xing L; Sun X
    Front Immunol; 2022; 13():852811. PubMed ID: 35422812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review.
    Agostara AG; Roazzi L; Villa F; Romano' R; Piscazzi D; Martinelli F; Ciarlo G; Oresti S; Travaglini F; Marando A; Sartore-Bianchi A; Giannetta L; Cerea G; Siena S; Pizzutilo EG; Signorelli D
    Expert Rev Respir Med; 2023; 17(9):787-803. PubMed ID: 37817448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
    Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
    BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?
    Bronte G; Cosi DM; Magri C; Frassoldati A; Crinò L; Calabrò L
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.